Friday, June 2, 2023

Subacromial Balloon Spacer - what is the evidence supporting the value of this innovation to patients with irreparable cuff tears?

Rotator cuff tears are one of the most common conditions of the shoulder. While many patients can accommodate the progressive age-related deterioration of the cuff with no or minimal symptoms, others have disabling symptoms and loss of function. Surgical management of symptomatic rotator cuff tears is commonly performed. For those tears that are not durably reparable, surgical options include (1) subacromial smoothing with debridement of hypertrophic bursa and the non-functioning margins of the tendon, possible biceps surgery, and manipulation as necessary to address glenohumeral stiffness, (2) partial repair, (3) superior capsular reconstruction, (4) reverse total shoulder and (5) the recently introduced Stryker InSpace subacromial balloon spacer. The InSpace device is a saline-filled biodegradable balloon that is inserted surgically in the space between the humerus and the acromion. In theory this device helps maintain the gap between the acromion and the humerus, and reduces friction.
The balloon received Food and Drug Administration (FDA) clearance in the USA in July, 2021, with approximately 29,000 devices having been implanted outside the USA before this.



The question is, in patients with symptomatic, irreparable rotator cuff tears, does adding a subacromial balloon spacer to debridement alone improve shoulder pain and function above what is achieved with debridement alone?

While small published case series have suggested encouraging clinical results, others have reported poor results or cases of inflammation and pain. For this reason, the authors of Subacromial balloon spacer for irreparable rotator cuff tears of the shoulder (START:REACTS): a group-sequential, double-blind, multicentre randomised controlled trial conducted a novel, efficient, adaptive clinical trial to assess the clinical effectiveness of a subacromial spacer balloon for people with symptomatic irreparable tears of the rotator cuff. This article was summarized in In Symptomatic Irreparable Rotator Cuff Tears, Adding a Subacromial Balloon Spacer to Debridement Resulted in Worse Shoulder Pain and Function at 12 Months.

The study was conducted by surgeons in 24 hospitals in the United Kingdom and included 117 patients (mean age, 67 years; 57% men) who had irreparable rotator cuff tears with disabling symptoms (pain and loss of function) and unsuccessful nonoperative management, and in whom surgery was warranted. Patients with reparable cuff tears, arthritis, pseudoparalysis, and subscapularis deficiency were excluded.

Eligibility was confirmed intraoperatively before randomly assigning (1:1) participants to a treatment group using a remote computer system. Using concealed allocation, patients were randomized to balloon spacer plus debridement (n = 56) or debridement alone (n = 61). Patients in the balloon spacer group received the Stryker InSpace balloon inserted by subspecialty-trained shoulder surgeons after arthroscopic debridement of the subacromial space and biceps tenotomy. Participants and assessors were masked to group assignment. Masking was achieved by using identical 1.5-cm lateral portal incisions for both procedures, blinding the operation note, and a consistent rehabilitation program offered regardless of group allocation.

The study was designed to have 90% power providing a robust answer to the clinical question.

The primary outcome was shoulder-related pain and function as measured by the Oxford Shoulder Score at 12 months. Secondary outcomes included the Western Ontario Rotator Cuff Index, EuroQol-5 Dimensions-5 Levels (EQ-5D-5L), and adverse events at 12 months. 97% of patients completed follow-up for the primary outcome. The primary outcome was the Oxford Shoulder Score at 12 months.

Pre-trial simulations using data from early and late timepoints informed stopping boundaries for two interim analyses. The study was designed to be terminated either for convincing evidence of a lack of benefit (futility) or for strong clinical benefit (efficacy). This exposes fewer people to risk of harm in the trial itself, as well as preventing harm or high costs for people having the treatment in the wider community. Having both futility and efficacy stopping rules allow a study to report early if an intervention is ineffective. Recruitment to this study was stopped when the predefined boundary for futility was crossed.

As seen in the figure and table below, in patients with symptomatic irreparable rotator cuff tears, adding the InSpace balloon to debridement only resulted in worse shoulder pain and function. The mean Oxford Shoulder Score at 12 months was 34·3 (SD 11·1) in the debridement only group and 30·3 (10·9) in the debridement with device group (mean difference adjusted for adaptive design –4·2 [95% CI –8·2 to –0·26];p=0·037) favoring debridement alone.












The adverse events for the two groups are shown below.




The authors concluded that for patients with symptomatic irreparable rotator cuff tears, adding a subacromial balloon spacer to debridement resulted in worse shoulder pain and function at 12 months.

Another recent study, InSpace Implant Compared with Partial Repair for the Treatment of Full-Thickness Massive Rotator Cuff Tears A Multicenter, Single-Blinded, Randomized Controlled Trial concluded that the outcomes of the InSpace implant were not superior to those of partial repair for the treatment of patients with irreparable, posterosuperior, massive rotator cuff tears and an intact subscapularis.









Recently, the authors of Outcomes of Subacromial Balloon Spacer Implantation for Irreparable Rotator Cuff Tears: A Systematic Review and Meta-Analysis reviewed the published evidence on the value of this procedure. Non of these authors had financial conflicts of interest related to the balloon.

Their review found 28 studies that were eligible for inclusion. 17 reported adequate pre- and postoperative data (mean and measure of variance) and thus were included in the meta-analysis.

894 shoulders (886 patients) had a mean age of 67.4 years (range, 61.7-76.2) with average follow-up of 30.4 months (range, 12-56). All patient reported outcomes and range of motion improved significantly from the preoperative baseline.  Device-related complications occurred at a rate of 3.6%, the most common of which were balloon migration (1.0%), synovitis (0.6%) and infection (0.8%). 5% of patients required salvage reverse shoulder arthroplasty.

Most of the identified reports of balloon implantation included other procedures performed at the same surgery, procedures which by themselves lead to improved shoulder comfort and function for patients with irreparable cuff tears: biceps surgery, partial or medialized cuff repair, and debridement. 

Comment: Clinical heterogeneity, use of concomitant procedures, and variations in patient selection limit the ability to interpret the available evidence. As a result the value of balloon implantation in comparison to currently accepted treatment strategies is unknown. In order to determine the true efficacy of the balloon, studies must compare outcomes of balloon placement to an identical control without balloon placement.

You can support cutting edge shoulder research that is leading to better care for patients with shoulder problems, click on this link.

Follow on twitter: https://twitter.com/shoulderarth
Follow on facebook: click on this link
Follow on facebook: https://www.facebook.com/frederick.matsen
Follow on LinkedIn: https://www.linkedin.com/in/rick-matsen-88b1a8133/

Here are some videos that are of shoulder interest
Shoulder arthritis - what you need to know (see this link).
How to x-ray the shoulder (see this link).
The ream and run procedure (see this link).
The total shoulder arthroplasty (see this link).
The cuff tear arthropathy arthroplasty (see this link).
The reverse total shoulder arthroplasty (see this link).
The smooth and move procedure for irreparable rotator cuff tears (see this link).
Shoulder rehabilitation exercises (see this link)